Evidence of microglial activation following exposure to serum from first-onset drug-naive schizophrenia patients

2018-01-01
van Rees, Geertje Frederique
Lago, Santiago Guillermo
Cox, David Alan
Tomasik, Jakub
Rustogi, Nitin
Weigelt, Karin
Özcan Kabasakal, Süreyya
Cooper, Jason
Drexhage, Hemmo
Leweke, F. Markus
Bahn, Sabine
Abnormal activation of brain microglial cells is widely implicated in the pathogenesis of schizophrenia. Previously the pathophysiology of microglial activation was considered to be intrinsic to the central nervous system. We hypothesised that due to their perivascular localization, microglia can also be activated by factors present in circulating blood. Through application of high-content functional screening, we show that peripheral blood serum from first-onset drug-naive schizophrenia patients is sufficient to provoke microglial cell signalling network responses in vitro which are indicative of proinflammatory activation. We further explore the composition of the serum for the presence of analytes, with the potential to activate microglia, and the utility of the resultant microglial cellular phenotype for novel drug discovery.
BRAIN BEHAVIOR AND IMMUNITY

Suggestions

Detection of hypothalamic neuropeptite levels involved in appetite regulation in aripiprazole treatment /
Özdemir, Serhat; Yanık, Tülin; Department of Biotechnology (2014)
Disruption or malfunctioning of neurotransmitter pathways, especially serotonergic and dopaminergic pathways are closely related to psychotic disorders such as schizophrenia. Antipsychotic medications are becoming widespread; however, in long term treatments, these drugs lead to considerable amount of weight gain as a side effect. Metformin, an antidiabetic drug, has previously been used to treat antipsychotic induced weight gain and aripiprazole has been defined as a neutral antipsychotic drug in terms of ...
Molecular investigation of ptz-induced epileptic activities in rat brain cell membranes and the effects of vigabatrin
Görgülü Türker, Sevgi; Severcan, Feride; Department of Biology (2009)
The epilepsies are a heterogenous group of symptom complexes, whose common features is the recurrence of seizures. There is no certain therapy for epilepsy. In order to promote new advances for the prevention of epilepsy the molecular mechanism of epileptic activities should be clarified. In the present study the goal is to obtain information for molecular mechanism of epilepsy. To achieve this, molecular alterations from pentylenetetrazol (PTZ)-induced epileptic activities on rat brain tissue and cell memb...
Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene-environment interaction. The EUGEI study
van Os, Jim; et. al. (Cambridge University Press (CUP), 2020-08-01)
Background First-degree relatives of patients with psychotic disorder have higher levels of polygenic risk (PRS) for schizophrenia and higher levels of intermediate phenotypes. Methods We conducted, using two different samples for discovery (n= 336 controls and 649 siblings of patients with psychotic disorder) and replication (n= 1208 controls and 1106 siblings), an analysis of association between PRS on the one hand and psychopathological and cognitive intermediate phenotypes of schizophrenia on the other ...
The Relationship Between Illness Duration And Brain Morphometry in Schizophrenia: Heschl's Gyrus and Prefrontal Cortex Volumetry
KARABAY, NURİ; ÖNİZ, ADİLE; Gökçay, Didem; ALPTEKİN, KÖKSAL; Hugdahl, Kenneth; ÖZGÖREN, MURAT (2013-01-01)
Introduction: The relationship between brain morphology and illness duration has been observed as a biomarker in psychiatric and neurologic patients, especially in schizophrenia. In this study, we aimed to investigate the relationship between the volumes of two target regions [prefrontal cortex (PFC) and Heschl's gyrus (HG)] and illness duration in schizophrenia. Such measurements can have implications for then understanding of cognitive impairments in schizophrenia.
Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway
Van Os, Jim; et. al. (2022-07-19)
Background There is evidence that environmental and genetic risk factors for schizophrenia spectrum disorders are transdiagnostic and mediated in part through a generic pathway of affective dysregulation. Methods We analysed to what degree the impact of schizophrenia polygenic risk (PRS-SZ) and childhood adversity (CA) on psychosis outcomes was contingent on co-presence of affective dysregulation, defined as significant depressive symptoms, in (i) NEMESIS-2 (n = 6646), a representative general population s...
Citation Formats
G. F. van Rees et al., “Evidence of microglial activation following exposure to serum from first-onset drug-naive schizophrenia patients,” BRAIN BEHAVIOR AND IMMUNITY, pp. 364–373, 2018, Accessed: 00, 2020. [Online]. Available: https://hdl.handle.net/11511/36427.